Overview of the current treatment landscape of ALK inhibitors

Overview of the current treatment landscape of ALK inhibitors

This is an actor representation of a hypothetical patient profile that was developed for educational purposes based on characteristics of patients with ALK+ non-small cell cancer, as can be seen in clinical practice. The hypothetical case was jointly developed by medical authors by employees with Cancer Network/Onn.

  1. Dr. Escape asks Dr. Garon: How would you describe the current treatment landscape for metastatic Alk+ NSCLC?
  • Which other treatment options could have been considered for this patient?

Leave a comment

Your email address will not be published. Required fields are marked *